• Lamotrigine: Advanced Protocols for Epilepsy and Cardiac Res

  2026-05-12

  Lamotrigine (6-(2,3-dichlorophenyl)-1,2,4-triazine-3,5-diamine) from APExBIO unlocks robust, reproducible workflows for studying sodium channel and serotonin signaling in neurological and cardiac models. This guide delivers protocol enhancements, troubleshooting strategies, and practical insights rooted in high-throughput BBB assays and validated reference data.

• Diethylmaleate in Oxidative Stress and Resistance Research

  2026-05-12

  Diethylmaleate is a powerful tool for dissecting antioxidant defense mechanisms and modeling resistance to oxidative stress in both cell and organismal assays. Recent studies highlight its precision in glutathione depletion and GST inhibition, enabling breakthroughs in toxicology and pest management research.

• Digoxin as a Na+/K+ ATPase Pump Inhibitor: Protocols & Innov

  2026-05-11

  Digoxin stands at the intersection of cardiovascular and virology research, offering potent Na+/K+ ATPase inhibition for both arrhythmia models and cell-type specific viral assays. This article equips scientists with actionable workflows, troubleshooting strategies, and translational insights leveraging APExBIO's high-purity Digoxin.

• 5-HT Reuptake Blockade Triggers Pyroptosis in BRAF V600E Mel

  2026-05-11

  Li et al. identify paroxetine hydrochloride as an inducer of pyroptosis and anti-tumor immunity in BRAF V600E-mutated melanoma by disrupting histone serotonylation and DNA repair. The study demonstrates the therapeutic potential of repurposing antidepressants for resistant melanoma, with implications for proteostasis and protein extraction workflows.

• Hydrazide-Based VEGFR-2 Inhibitors: Advances in Antiangiogen

  2026-05-10

  This study reports the design, synthesis, and evaluation of 53 novel hydrazide-based VEGFR-2 inhibitors, highlighting SA7 as a lead compound with potent antiangiogenic and antiproliferative activity. The research underscores the therapeutic relevance of targeting VEGFR-2 in cancer biology and establishes new chemical tools comparable to established agents such as sorafenib.

• Fludarabine: DNA Synthesis Inhibitor Workflows for Oncology

  2026-05-09

  Fludarabine’s precise DNA synthesis inhibition unlocks reproducible cell cycle arrest and apoptosis in advanced leukemia and multiple myeloma research. This guide delivers actionable workflow enhancements, troubleshooting strategies, and translational insights, leveraging APExBIO’s rigorously characterized Fludarabine for next-generation oncology studies.

• Gamma-linolenic Acid (GLA): Precision Immunomodulation in An

  2026-05-08

  Explore how gamma-linolenic acid (GLA) advances anti-inflammatory research with precision immunomodulation. This article uncovers unique mechanistic insights and assay strategies, connecting GLA's pharmacology to practical, evidence-based applications.

• HDAC Inhibition Reverses EBV-Driven Plasticity in NPC Cells

  2026-05-08

  This study uncovers how EBV-induced dedifferentiation in nasopharyngeal carcinoma (NPC) is mediated by LMP1-driven epigenetic repression of CEBPA. It demonstrates that histone deacetylase (HDAC) inhibition can restore differentiation, offering a mechanistic rationale for differentiation therapy in solid tumors.

• ERK Inhibition Mitigates Mitochondrial Fragmentation and Aut

  2026-05-07

  Yuan et al. uncover that ERK inhibition protects SH-SY5Y cells from oxygen-glucose deprivation/reoxygenation injury by downregulating Drp1-mediated mitochondrial fragmentation and autophagy. These findings clarify mechanistic links in cerebral ischemia-reperfusion injury and suggest new intervention strategies.

• Dabigatran Etexilate: Transforming Oral Anticoagulation in V

  2026-05-07

  This review details the innovation of dabigatran etexilate as the first oral direct thrombin inhibitor for venous thromboembolism (VTE) and atrial fibrillation (AF). The study highlights its predictable anticoagulant effects, reduced need for monitoring, and clinical impact relative to traditional therapies.

• Prochlorperazine (SKU A8508): Reliable Assay Solutions in Ca

  2026-05-06

  This scenario-driven article demonstrates how Prochlorperazine (SKU A8508) from APExBIO delivers reproducible, evidence-based solutions for cell viability, proliferation, and cytotoxicity assays in oncology and antiviral research. We address experimental design, protocol optimization, data interpretation, and vendor selection, providing actionable insights for biomedical scientists aiming for high assay fidelity and translational relevance.

• Macrophage Polarization via TLR4 Pathway in Colitis-Associat

  2026-05-06

  Liu et al. demonstrate that Jiedu Xiaozheng Yin (JXY) attenuates colitis-associated colorectal cancer (CAC) progression by promoting macrophage polarization towards the pro-inflammatory M1 phenotype through TLR4 signaling. This mechanistic insight highlights the immunomodulatory potential of TCM compounds in tumor microenvironment regulation and offers a foundation for future chemopreventive strategies.

• Lipid Scrambling in Ferroptosis: TMEM16F as a Key Regulator

  2026-05-05

  Yang et al. reveal the role of TMEM16F-mediated lipid scrambling in regulating the terminal phase of ferroptosis. Disruption of this process heightens sensitivity to ferroptosis and promotes tumor immune rejection, suggesting new therapeutic strategies for cancer.

• Streptozotocin in Diabetes Research: Applied Protocols & Inn

  2026-05-05

  Streptozotocin (STZ) remains the gold-standard tool for modeling experimental diabetes mellitus and β-cell apoptosis induction in vivo and in vitro. This article leverages recent mechanistic and workflow advances—including those spotlighted in the 2024 TBK1-diabetic neuropathy study—to deliver actionable protocols, troubleshooting guidance, and integration with emerging neuroinflammatory research.

• WZ4003: Applied NUAK1/2 Inhibition for Cancer and Tauopathy

  2026-05-04

  WZ4003 enables precise dissection of NUAK1/2 kinase roles in cell migration, proliferation, and tau phosphorylation. Its high selectivity and validated workflows make it a leading choice for both cancer and neurodegenerative disease models, setting new standards for experimental rigor and specificity.

484 records 14/33 page Previous Next First page 上5页 1112131415 下5页 Last page